CJC-1295 DAC

CJC-1295 DAC is a modified analogue of human growth hormone-releasing factor (hGRF). The peptide is based on the hGRF(1-29) sequence and contains amino acid substitutions together with a C-terminal maleimide-containing modification. This modification is central to the compound's distinctive research profile because it provides a reactive group capable of forming a covalent bond with the free thiol of cysteine-34 on serum albumin. Research has used this property to investigate peptide–albumin bioconjugation and the relationship between structural modification and peptide stability.

GHRH Receptor Interaction

CJC-1295 has been investigated as an analogue of GHRH that interacts with the growth hormone-releasing factor (GRF) receptor. Experimental research has demonstrated receptor activity using cultured rat anterior pituitary cells and receptor-related experimental models. [1] These studies provide a basis for investigating CJC-1295 at the receptor and peptide-signaling level without treating the compound as equivalent to native hGRF.

DAC and Albumin-Binding Chemistry

The defining feature of the CJC-1295 DAC form is its reactive maleimide derivative. The maleimide group can react with the free thiol of Cys34 on serum albumin, producing a peptide–albumin conjugate. This chemistry provides a useful model for studying covalent peptide–protein conjugation and how structural modifications can alter the behavior and stability of peptide molecules in experimental systems. [2]

Research into Peptide Stability

Experimental studies have also examined how albumin conjugation affects the stability of CJC-1295 compared with unmodified hGRF(1-29). In vitro work reported enhanced resistance to dipeptidylpeptidase-IV following albumin conjugation, providing a basis for studying the relationship between peptide modification, proteolytic stability, and molecular structure.

CJC-1295 DAC Research Applications

CJC-1295 with DAC has been investigated in several areas of peptide and receptor research, particularly where researchers are interested in modified GHRH analogues, albumin-binding chemistry, and GHRH receptor activity. The available literature is primarily focused on experimental pharmacology and molecular characterization.

GHRH Receptor Research

CJC-1295 with DAC has been studied as a modified GHRH analogue in experimental receptor systems. Research has examined its ability to interact with the GHRH receptor and retain receptor-directed activity following structural modification. These studies provide a model for investigating how changes to a peptide sequence and the addition of a DAC moiety affect receptor recognition and activity.

Albumin-Binding and Bioconjugation Research

The DAC modification makes CJC-1295 particularly relevant to peptide–protein bioconjugation research. Its maleimide-containing group can react with the free thiol of cysteine-34 on serum albumin, creating a covalent peptide–albumin conjugate. [2] This provides an experimental model for studying site-specific conjugation, albumin-binding chemistry, and the relationship between peptide structure and protein association.

Peptide Stability Research

Researchers have also investigated CJC-1295 in relation to peptide stability and resistance to enzymatic degradation. Experimental work has compared modified GRF analogues with native hGRF(1-29), including studies examining resistance to dipeptidyl peptidase-IV and the effect of albumin conjugation on peptide stability. These studies can help characterize how chemical modifications influence the persistence and integrity of peptide molecules in experimental systems.

Modified Peptide Design

CJC-1295 with DAC provides a model for studying how multiple structural modifications can alter the properties of a peptide. Its modified GRF(1-29) backbone and additional albumin-binding group allow researchers to examine the relationship between peptide sequence, chemical modification, proteolytic stability, and receptor-directed activity.

Analytical and Comparative Research

CJC-1295 with DAC can also be used as a defined research material for analytical characterization and comparison with related peptide analogues. Relevant research questions include confirming molecular identity, evaluating purity, characterizing structural modifications, and comparing the DAC form with non-DAC GRF analogues such as Modified GRF(1-29).

CJC-1295 DAC Compared With Related Research Peptides

CJC-1295 with DAC, CJC-1295 without DAC, and Sermorelin are all related to GHRH research but represent distinct peptide constructs. Comparing them highlights differences in sequence, structural modification, receptor activity, and the research questions each material can support.

Note: All materials listed for laboratory research use only

Other GHRH-Related Research Peptides

Tesamorelin provides another useful comparison because it is a synthetic GHRH analog that can be studied through the same GHRH receptor system, while its sequence and structural characteristics differ from CJC-1295. CJC-1295 No DAC is an especially direct comparator because it retains the CJC-1295-related GHRH framework without the DAC modification. 

Together, these research materials provide useful models for comparing how peptide sequence and chemical modification influence GHRHR recognition and downstream signaling.

Storage & Laboratory Handling

CJC-1295 with DAC is supplied as a lyophilized research material. Standard laboratory practices for peptide storage and handling should be used to help maintain sample integrity:

• Keep the vial tightly sealed when not being handled.

• Store the material at the temperature specified by the manufacturer and appropriate to the intended storage period.

• Protect the peptide from excessive heat, light, and moisture.

• Minimize unnecessary exposure to ambient humidity when handling the vial.

• Avoid unnecessary freeze–thaw cycles and temperature fluctuations, which can contribute to peptide degradation.

• When moving a refrigerated or frozen vial to a different environment, keep the container sealed while it equilibrates to help minimize condensation.

• Use appropriate clean laboratory handling practices to reduce the risk of contamination.

• Maintain the original product labeling and batch/lot traceability, including the corresponding Certificate of Analysis (COA).

• Follow applicable laboratory procedures for the handling, storage, and documentation of research peptides.

Peptide stability can vary according to molecular structure, formulation, storage conditions, and experimental environment. Therefore, there’s no universal shelf life or stability profile and researchers should rely on available product-specific documentation and validated laboratory procedures.

When you buy CJC-1295 with DAC from Bluum Peptides, check the relevant product documentation for storage and handling guidelines for the appropriate procedures.

Certificate of Analysis & Quality Assurance

Bluum Peptides tests every new batch of CJC-1295 with DAC through independent third-party laboratories. Testing covers purity, identity, sterility, endotoxins, and other applicable analytical parameters, with results documented in a batch-specific Certificate of Analysis (COA).

Researchers can use the Bluum Peptides COA Lookup page to access available certificates and review the analytical results for individual batches. COAs can also be traced to the independent laboratory that performed the testing, providing additional transparency into the reported results.

Frequently Asked Questions

What is CJC-1295 with DAC?

CJC-1295 with DAC is a synthetic analogue of human growth hormone-releasing factor (hGRF) that incorporates a Drug Affinity Complex (DAC) modification. The modified peptide has been investigated in research involving GHRH receptor activity, peptide modification, albumin-binding chemistry, and peptide stability.

What does DAC mean in CJC-1295?

DAC stands for Drug Affinity Complex. In CJC-1295, the DAC modification includes a reactive group that can form a covalent bond with cysteine-34 of serum albumin. This albumin-binding chemistry is a defining structural feature of CJC-1295 with DAC and distinguishes it from related non-DAC GRF analogues.

What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?

The primary difference is the presence of the DAC modification. CJC-1295 with DAC contains the albumin-binding modification, while material commonly marketed as CJC-1295 without DAC generally refers to Modified GRF (1-29), which lacks the DAC group. Because the two materials have different molecular structures, they should be treated as distinct research materials rather than interchangeable products.

What is CJC-1295 with DAC used for in research?

CJC-1295 with DAC has been studied in research involving GHRH receptor activity, modified peptide structure, albumin–peptide bioconjugation, and peptide stability. Its defined structural modification also makes it useful for comparative research examining how chemical modifications affect peptide properties and receptor-directed activity.

How is CJC-1295 with DAC tested for purity and identity?

CJC-1295 with DAC can be evaluated using analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS). HPLC can be used to assess chromatographic purity, while mass spectrometry can help confirm the molecular identity and mass characteristics of the peptide. Together, these methods provide complementary information about the composition and identity of the analyzed material. Researchers should review the specific analytical methods, acceptance criteria, and reported results in the batch-specific Certificate of Analysis (COA).

Does Bluum Peptides provide a Certificate of Analysis for CJC-1295 with DAC?

Yes. Bluum Peptides provides a batch-specific Certificate of Analysis (COA) for its CJC-1295 with DAC research material. The COA documents the analytical results associated with the specific production lot, including applicable purity and identity testing. If you buy CJC-1295 with DAC from Bluum Peptides, you can use the Lab Reports page to review available batch documentation and trace the reported testing to the independent laboratory responsible for the analysis.

Where can I buy CJC-1295 with DAC for research?

CJC-1295 with DAC for sale is available from Bluum Peptides as a laboratory research product. The product is supplied as a lyophilized material with batch-specific analytical documentation. It is sold strictly for research use only and is not intended for human or veterinary use.

1. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8.
   doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PMID: 15817669.

2. Yu X, Ruan M, Wang Y, Nguyen A, Xiao W, Ajena Y, Solano LN, Liu R, Lam KS. Site-Specific Albumin-Selective Ligation to Human Serum Albumin under Physiological Conditions. Bioconjug Chem. 2022 Dec 21;33(12):2332-2340.
   doi: 10.1021/acs.bioconjchem.2c00361. Epub 2022 Nov 9. PMID: 36350013; PMCID: PMC9782315.